Method for detecting various pathogenic fungi by TaqMan probe method based on automatic fluorescent quantitative PCR (Polymerase Chain Reaction) algorithm

Through automatic fluorescence quantitative PCR algorithm and TaqMan probe method, combined with specific primers and probes, efficient detection of multiple pathogenic fungi is achieved, solving the problem of difficulty in screening of existing tools, and reducing the antifungal preventive treatment Waste and side effects, suitable for screening of immunosuppressive patients.

CN119020520APending Publication Date: 2024-11-26NANJING DRUM TOWER HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411074345.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-07
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing pathogenic fungi detection tools are difficult to effectively screen out multiple pathogenic fungi, especially in immunosuppressive patients, resulting in waste and side effects of antifungal preventive treatment, and existing tools fail to cover most pathogenic fungi. .

Method used

The TaqMan probe method based on automatic fluorescence quantitative PCR algorithm is adopted, combined with specific primers and probe combinations, and the simultaneous identification of multiple pathogenic fungi and Test.

Benefits of technology

It has achieved high sensitivity and specificity for pathogenic fungi detection in a short period of time, can cover more than 93% of pathogenic fungi, reduce false positives, and is suitable for screening for all patients who require antifungal preventive treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020520A_ABST
    Figure CN119020520A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of pathogenic bacterium detection, and particularly discloses a method for detecting various pathogenic fungi by a TaqMan probe method based on an automatic fluorescent quantitative PCR (Polymerase Chain Reaction) algorithm. The invention also discloses a combination of a primer and a probe for detection, wherein the primer comprises a forward primer F1: 5 '-GCGCGYTACATGACRGRGC-3' and a reverse primer R1: 5 '-ACCTTGTTACGACTTTTASTTCCTAATGACC-3', and the reverse primer R1: 5 '-GCGCGYTACATGACRGC-3' is 5 '-GCGCGYTACATGACRGC-3' is 5 '-GCGCGYTACATGACRGC-3'. The probe is Probe 1-MGB: 5 '6-FAM-TCGTGCTGGGGGATAGAGCAT-MGB 3', and the probe is a fluorescent probe. By using the method provided by the invention, the primer and probe combination and an algorithm are combined, so that whether pathogenic fungi exist in a sample to be detected or not and the number of possible fungal cells can be identified in a relatively short time (2-3 hours); the sensitivity is high, and at least 10 bacteria / ml can be detected; the method has the advantages of simple operation, good specificity, less false positive condition, wide coverage range of detected pathogenic fungi, and good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pathogen detection, and specifically discloses a method for detecting multiple pathogenic fungi by TaqMan probe method based on automatic fluorescence quantitative PCR algorithm, and also discloses a combination of primers and probes used in the above detection method, and a detection kit prepared thereby. Background Art

[0002] Invasive fungal infections have always been one of the main causes of worsening conditions and increased mortality in immunosuppressed patients. Immunosuppressed patients include HIV patients (39 million), cancer patients receiving chemotherapy (20 million), and organ transplant patients (400,000), totaling nearly 60 million people worldwide. Clinically, antifungal preventive treatment is often used for the above patients, that is, antifungal drugs are given without any microbiological indications to prevent the occurrence of invasive fungal infection events. Antifungal preventive treatment not only wastes medical resources and patients' money, but also causes toxic side effects such as liver toxicity and kidney toxicity, thereby increasing the risk of death in the above population. So far, 637 pathogenic fungal species and potential pathogenic fungi that have been reported to cause invasive fungal infections have been reported, while the number of fungal species that can be easily cultured under laboratory conditions does not exceed 15% of the total number of pathogenic fungal species. Therefore, the development of pan-fungal detection tools for pathogenic fungal species with the help of molecular methods is one of the key measures for clinical rational antifungal treatment.

[0003] So far, molecular detection tools for pathogenic fungi mainly use ribosomal DNA (18S or ITS), conserved housekeeping genes (chs1, topoisomerase II), etc. Although the above fragments or genes are somewhat conserved among different fungi, current molecular detection tools mainly distinguish different pathogenic fungal groups (species or genus level) by combining conserved regions with variable regions. No researchers have yet proposed the development and exploration of pan-fungal detection tools for most pathogenic fungi, that is, pan-fungal detection technology for screening populations such as HIV patients, cancer patients receiving chemotherapy, and organ transplant patients needs to be developed. Summary of the invention

[0004] To solve the above problems, the present invention provides a method for detecting multiple pathogenic fungi using a TaqMan probe method based on an automatic fluorescence quantitative PCR algorithm.

[0005] The present invention includes the following technical solutions:

[0006] The present invention discloses a method for detecting multiple pathogenic fungi using a TaqMan probe method based on an automatic fluorescence quantitative PCR algorithm, which is characterized by comprising the following steps:

[0007] (1) Template DNA extraction:

[0008] (11) Sample pretreatment:

[0009] (12) Preparation of cracking system:

[0010] (13) Automated nucleic acid extraction:

[0011] (14) Collection of DNA:

[0012] (2) TaqMan probe qPCR amplification reaction:

[0013] (3) Determination of results.

[0014] The present invention also discloses a primer and probe combination for simultaneously identifying multiple pathogenic fungi, wherein the primer comprises:

[0015] Forward primer F1: 5'-GCGCGYTACACTGACRGRGC-3' and

[0016] Reverse primer R1: 5′-ACCTTGTTACGACTTTTASTTCCTCTAAATGACC-3′;

[0017] The probe is Probe 1-MGB: 5'6-FAM-TCGTGCTGGGGATAGAGCAT-MGB 3'.

[0018] Furthermore, the present invention discloses a detection reagent for simultaneously identifying multiple pathogenic fungi, comprising the above primer and probe combination.

[0019] Furthermore, the present invention discloses a detection kit for simultaneously identifying multiple pathogenic fungi, comprising the above primer and probe combination.

[0020] Furthermore, the above-mentioned detection kit for simultaneously identifying multiple pathogenic fungi includes a TaqMan probe method qPCR amplification reaction system:

[0021] (1) Reaction solution: AceQ reaction premix: AceQ U+Probe Master Mix;

[0022] (2) Primer solution: including forward primer F1, reverse primer R1, and probe Probe 1-MGB. The primer and probe combinations are:

[0023] Forward primer F1: 5′-GCGCGYTACACTGACRGRGC-3′;

[0024] Reverse primer R1: 5′-ACCTTGTTACGACTTTTASTTCCTCTAAATGACC-3′;

[0025] Probe 1Probe 1-MGB:

[0026] 5'6-FAM-TCGTGCTGGGGATAGAGCAT-MGB 3';

[0027] (3) DEPC water: sterile water without nuclease.

[0028] Furthermore, in the above-mentioned detection kit for simultaneously identifying multiple pathogenic fungi, the concentrations of the forward primer F1, the reverse primer R1 and the probe Probe 1-MGB are all 10 pmol / μl.

[0029] Furthermore, the present invention discloses an application of the above-mentioned detection kit for simultaneously identifying multiple pathogenic fungi, comprising the following steps:

[0030] (1) Template DNA extraction:

[0031] (11) Sample pretreatment:

[0032] (12) Preparation of cracking system:

[0033] (13) Automated nucleic acid extraction:

[0034] (14) Collection of DNA:

[0035] (2) TaqMan probe qPCR amplification reaction:

[0036] (3) Result determination:

[0037] The applications include scientific research or the development of related drugs, but do not include the diagnosis and treatment of diseases.

[0038] Furthermore, in the application of the above-mentioned detection kit for simultaneously identifying multiple pathogenic fungi, the sample in (11) includes one or more of a sputum sample, a bronchoalveolar lavage fluid sample and a clinically isolated fungus.

[0039] Furthermore, in the application of the above-mentioned detection kit for simultaneously identifying multiple pathogenic fungi, the (2) TaqMan probe method qPCR amplification reaction comprises the following steps:

[0040] Use 200μl PCR tubes to prepare the reaction system, set up three replicates, forward primer F1 and reverse primer R1 are 0.4μl, probe Probe 1Probe 1-MGB 0.3μl, AceQ reaction premix 10μl, template DNA 2μl, make up to 20μl with DEPC-water, mix the reaction solution evenly and transfer it to a 96-well qPCR plate to avoid bubbles; use a sealing film to seal the tube mouth, place the above 96-well reaction tube on the qPCR instrument for amplification reaction; the reaction program is as follows: Stage 1 37℃, 3min; Stage 2 95℃, 5min; Stage 3 (95℃, 10s; 70℃, 20s), 40 cycles.

[0041] Furthermore, in the application of the above-mentioned detection kit for simultaneously identifying multiple pathogenic fungi, the (3) result determination includes the following steps: using a fluorescent PCR instrument to detect the fluorescent signal in the reaction tube in real time, calculating the real-time amplification curve, and using the baseline to determine the Ct value in the reaction well to be tested, and by combining the Ct value and the shape of the amplification curve to determine whether the reaction well to be tested is positive or negative, as well as the bacterial load.

[0042] Furthermore, in the application of the above-mentioned detection kit for simultaneously identifying multiple pathogenic fungi, the (3) result determination comprises the following steps:

[0043] (31) When the positive control shows a Ct value and an "S"-shaped amplification curve, and the negative control has no Ct value and an "S"-shaped amplification curve, it indicates that there is no problem with the entire detection process and the test results of the sample to be tested are credible;

[0044] (32) When the conditions in (1) are met, the detection well of the sample to be tested shows a Ct value and an "S"-shaped amplification curve, indicating that the pathogenic fungus in the sample to be tested is positive, or; the detection well of the sample to be tested does not show a Ct value and an "S"-shaped amplification curve, indicating that the pathogenic fungus in the sample to be tested is negative;

[0045] (33) When the positive test conditions in (2) are met, combined with the standard curve, the content of pathogenic fungi decreases 10-fold for every increase of Ct by about 4;

[0046] The Ct value of the test well of the sample to be tested meets the following conditions, that is, positive detection, and includes the intensity level classification of bacterial load: that is, 18≤Ct≤22, intensity level IV; 22≤Ct≤26, intensity level III; 26≤Ct≤30, intensity level II; 30≤Ct≤34, intensity level I;

[0047] When the positive control lacks a Ct value or an "S"-shaped amplification curve, or the negative control has a Ct value and an "S"-shaped amplification curve, it indicates that there is a problem with the entire detection process, or there is contamination, and the test results of the sample to be tested are unreliable, and the test operation needs to be repeated to further determine the situation in the sample to be tested.

[0048] The present invention has the following beneficial effects:

[0049] The present invention belongs to the field of pathogen detection, and specifically discloses a method for detecting multiple pathogenic fungi by TaqMan probe method based on automatic fluorescence quantitative PCR algorithm, and also discloses a combination of primers and probes used in the above detection method, and a detection kit prepared thereby, which has the following advantages:

[0050] (1) Easy to implement. The primer and probe combination disclosed in the present invention and the kit prepared therefrom are easy to operate, and the detection method used can identify whether pathogenic fungi are present in the sample to be tested, as well as the possible number of fungal cells, in a relatively short time (2 to 3 hours);

[0051] (2) High sensitivity. The number of copies of 18S rDNA in pathogenic fungi ranges from 10 to 1200, and the number of copies in most pathogenic fungi is above 100. Therefore, the minimum number that can be detected is 10 bacteria / ml.

[0052] (3) Good specificity. Based on the comparison and analysis results of 18S rDNA sequences of pathogenic fungi, humans, model plants and animals, the present invention designs primer pairs for specific amplification of pathogenic fungi, and combines them with TaqMan probes to achieve the purpose of specific identification of pathogenic fungi without generating false positives.

[0053] (4) Wide coverage. The detection range of the present invention includes all available 18S rDNA sequences of pathogenic fungi. On the basis of ensuring specific detection, it can simultaneously determine the presence of more than 93% of pathogenic fungi (theoretically, after comparison, there are 430 pathogenic fungi with target sequences and covered by the primer-probe combination of the present invention, and there are 462 pathogenic fungi with available 18S sequences (Table 2);

[0054] (5) Wide application scenarios. The kit and method described in the present invention are suitable for screening pathogenic fungi in all patients who need antifungal preventive treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 The research roadmap of the present invention;

[0056] Figure 2 The primer-probe combination of the present invention is designed based on the principle of TaqMan probe method;

[0057] Figure 3 Agarose gel electrophoresis diagram of setting annealing temperature gradient based on primer Tm value;

[0058] Figure 4 Standard curve of the primer-probe combination of the present invention tested using Candida albicans genomic DNA. DETAILED DESCRIPTION

[0059] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0060] The reagents or instruments used in the examples of the present invention without indicating the manufacturer are all conventional reagent products that can be obtained through commercial purchase.

[0061] AceQ reaction premix (Nanjing Novozyme Biotech Co., Ltd., Nanjing, China, product number Q113)

[0062] Example 1

[0063] The research design idea of ​​the present invention is as follows Figure 1 As shown. Based on the list of 307 pathogenic fungi reported by previous researchers (Taylor et al., 2001) and the literature review, a total of 637 pathogenic fungi that can cause human infection or have potential pathogenicity were finally confirmed (Table 1); the 18S sequences of the corresponding species were retrieved and collected in the NCBI database using the species name (Latin name), and a total of 462 18S sequences of pathogenic fungi were available (Table 2); at the same time, the 18S full-length sequences of the host human, as well as several model animals and plants were collected as controls, and the obtained sequences were compared and analyzed using MEGA software, and specific amplification primers and TaqMan probes were designed for DNA regions that were conserved among pathogenic fungi and varied in the corresponding regions of the host human, as well as several model animals and plants ( Figure 2 ), theoretically, after comparison, there are 430 pathogenic fungi with target sequences and covered by primer-probe combinations in the present invention, and 462 pathogenic fungi with 18S sequences available, which can simultaneously determine the presence of more than 93% of pathogenic fungi. The annealing temperature gradient is set at 64°C to 72°C, and candidate temperatures are first screened by ordinary PCR. As the annealing temperature increases, the influence of genomic DNA of other species on the amplification primers becomes weaker and weaker, and the purpose of specific amplification of the target fungi is achieved at 68°C ( Figure 3); further use the TaqMan probe method to screen the appropriate amplification program, with the increase of the extension temperature, the influence of genomic DNA of other species on the primer probe combination pair is getting weaker and weaker, and the purpose of specific detection of target fungi is achieved at 70°C, that is, there is no interference of any false positive Ct value, and the R2 of the standard curve is 1.000, and the verification of sample B131 identified as pathogenic fungi by NGS is obtained; in addition, when the extension temperature is further increased, although the influence of genomic DNA of other species does not exist, the lowest concentration of positive control (i.e., adding 0.0002ng of sample well) does not show a positive signal, indicating that the high temperature of 72°C seriously affects the amplification efficiency and detection accuracy of the primer probe combination. In summary, the optimal extension temperature is finally determined to be 70°C, which not only eliminates the false positive situation, but also ensures the accuracy of detection (Table 3).

[0064] Table 1 Potential pathogenic fungi and coverage of the target sequences of the present invention (partial, for reference, details in the supporting documents)

[0065]

[0066] Table 2 Pathogenic fungi for which 18S sequences are available (partial, for reference, details in the supporting documents)

[0067]

[0068] Table 3 Detection results of the qPCR probe method for different extension temperature gradients in the invention

[0069]

[0070] Note: The DNA gradient dilution sample of the positive control is the DNA extraction sample of the clinically isolated Candida albicans strain; B131 is the sample number of the clinical NGS test to determine the presence of pathogenic fungi; A549 is the DNA sample number of the human non-small cell lung cancer cell line; Les is the DNA sample number extracted from tomato leaves; Sau is the DNA sample number of the clinically isolated Staphylococcus aureus; N represents the negative control.

[0071] Example 2

[0072] Preparation of TaqMan probe qPCR amplification reaction system:

[0073] (1) Reaction solution: AceQ reaction premix (AceQ U+Probe Master Mix); the AceQ reaction premix (AceQ U+Probe Master Mix) was purchased from Nanjing Novozymes Biotech Co., Ltd. All premix reagents that can meet the requirements of qPCR probe method detection are applicable in the present invention;

[0074] (2) Primer solution: including forward primer F1 (10 pmol / μl), reverse primer R1 (10 pmol / μl), and probe Probe1-MGB marker (10 pmol / μl). The primer and probe combinations are:

[0075] Forward primer F1: 5'-GCGCGYTACACTGACRGRGC-3' (SEQ ID No. 1);

[0076] Reverse primer R1: 5'-ACCTTGTTACGACTTTTASTTCCTCTAAATGACC-3' (SEQ ID No. 2);

[0077] Probe 1: 5'6-FAM-TCGTGCTGGGGATAGAGCAT-MGB 3' (SEQ ID No. 3);

[0078] (3) DEPC water: sterile water without nuclease.

[0079] Example 3

[0080] The pathogenic fungi were identified using the reaction system of Example 2 in the following manner. The sample to be tested in this example is a patient's sputum or bronchoalveolar lavage fluid sample that has been identified as a pathogenic fungus; of course, it can also be a pathogenic fungus that has been clinically identified and isolated.

[0081] 1. Template DNA extraction:

[0082] (1) Sample pretreatment:

[0083] Sputum sample: Take an appropriate amount of sputum sample, add 5 times the volume of N-acetylcysteine ​​solution (10g / L), shake and mix for 30 minutes, centrifuge at 6000xg for 10 minutes, and discard the supernatant. Resuspend the precipitate with 200μl PBS and transfer to LysisTube2;

[0084] Bronchoalveolar lavage fluid sample: After oscillation and mixing, take 400 μl of bronchoalveolar lavage fluid sample and transfer it to Lysis Tube2;

[0085] Clinically isolated fungi: Pick pathogenic fungal colonies from the plate and add them to 400 μl of sterile saline, shake and mix, and then transfer to Lysis Tube2;

[0086] (2) Preparation of cracking system:

[0087] 40 μl Proteinase K and 220 μl Lysis Buffer 3 were added to the Lysis Tube 2 with the sample added, and the Lysis Tube 2 was placed on a vortexer and vortexed at the maximum speed for 10 min. After vortexing, centrifugation was performed at 13800×g for 5 min, and 330 μl of the supernatant was transferred to the first and seventh columns of the 96-deep well plate reagent (Nanjing Novogene Biotech Co., Ltd., Nanjing, China, product number RM602), followed by the fully automated nucleic acid extraction step.

[0088] (3) Automated nucleic acid extraction:

[0089] Place the 96-deep-well plate in the fully automatic nucleic acid extractor in the correct direction, install the magnetic rod cover, and make sure it is inserted to the bottom; select the RM602 program, press the start button, and perform automated extraction.

[0090] (4) Collecting DNA:

[0091] After the automated extraction procedure is completed, transfer the eluate in the wells of columns 6 and 12 to clean Nuclease-free centrifuge tubes, label the sample name and date, and the eluted product can be used directly in downstream experiments or stored at -20°C for future use.

[0092] 2. TaqMan probe qPCR amplification reaction:

[0093] The reaction system was prepared in a 200 μl PCR tube, with three replicates. The forward primer (SEQ ID No. 1) and the reverse primer (SEQ ID No. 2) were both 0.4 μl, the probe (SEQ ID No. 3) was 0.3 μl, the AceQ reaction premix (Nanjing Novozymes Biotech Co., Ltd., Nanjing, China, product number Q113) was 10 μl, and 2 μl of template DNA was added. The mixture was made up to 20 μl with DEPC-water. The reaction solution was mixed evenly and transferred to a 96-well qPCR plate to avoid bubbles. The tube mouth was sealed with a sealing film, and the 96-well reaction tube was placed on a qPCR instrument for amplification reaction. The detailed reaction procedure was as follows: Stage 1 37°C, 3 minutes; Stage 2 95°C, 5 minutes; Stage 3 (95°C, 10 seconds; 70°C, 20 seconds), 40 cycles.

[0094] 3. Result determination:

[0095] The fluorescence signal in the reaction tube is detected in real time using a fluorescence PCR instrument. Based on the principle of fluorescence quantitative PCR, there is a quantitative relationship between the fluorescence signal and the number of amplification cycles, and the system can automatically calculate the real-time amplification curve. With the help of the baseline (the PCR cycle where the fluorescence signal accumulates but is below the detection limit, the baseline is usually set to the fluorescence signal at 3 to 15 cycles), the Ct value in the reaction well to be tested can be determined. The threshold is arbitrarily selected by the computer based on the change of the baseline, which refers to 10 times the standard deviation of the mean of the baseline fluorescence signal of 3 to 15 cycles. The fluorescence signal above the threshold is the real signal, which is used to define the sample threshold cycle number. Ct refers to the PCR cycle number when the fluorescence intensity is greater than the minimum detection level (i.e., the fluorescence threshold). By substituting the Ct value of the reaction well of the sample to be tested into the standard curve, the bacterial load in the sample to be tested, i.e., the approximate number of cells of the pathogenic fungus, can be calculated. The authenticity and validity of the positive signal in the reaction well are guaranteed by combining the Ct value with the shape of the amplification curve.

[0096] The detailed judgment method and standards are as follows: (1) When the positive control shows a Ct value and an "S"-shaped amplification curve, and the negative control has no Ct value and an "S"-shaped amplification curve, it indicates that there is no problem with the entire detection process and the detection result of the sample to be tested is credible; (2) When the conditions in (1) are met, the detection well of the sample to be tested shows a Ct value and an "S"-shaped amplification curve, indicating that the pathogenic fungus in the sample to be tested is positive, or; the detection well of the sample to be tested does not show a Ct value and an "S"-shaped amplification curve, indicating that the pathogenic fungus in the sample to be tested is positive. Pathogenic fungi are negative; (3) when the positive detection conditions in (2) are met, combined with the standard curve, the content of pathogenic fungi decreases by 10 times for every increase of Ct by about 4; the Ct value of the test well of the sample to be tested meets the following conditions, that is, positive detection, and includes the intensity level classification of bacterial load, that is, 18≤Ct≤22, intensity level IV; 22≤Ct≤26, intensity level III; 26≤Ct≤30, intensity level II; 30≤Ct≤34, intensity level I.

[0097] On the contrary, when the positive control lacks a Ct value or an "S"-shaped amplification curve, or the negative control has a Ct value and an "S"-shaped amplification curve, it indicates that there is a problem with the entire detection process, or there is contamination, and the test results of the sample to be tested are unreliable, and the test operation needs to be repeated to further determine the situation in the sample to be tested.

[0098] Table 4 Test results of the present invention for clinical alveolar lavage fluid or sputum samples

[0099] sample serial number Ct value Culture results NGS Results DNA B011 34.33 34.65 34.28 Negative Not tested DNA B071 NA NA NA Negative Negative DNA B073 NA NA NA Negative Not tested DNA B131 32.05 32.14 32.43 Negative Aspergillus spp., Pneumocystis jiroveci DNA B113 NA NA NA Negative Not tested DNA B211 NA NA NA Negative Not tested DNA B271 NA NA NA Negative Not tested DNA B031 NA NA NA Negative Negative DNA B051 NA NA NA Negative Negative DNA B111 32.96 32.91 32.84 Negative Not tested DNA B291 NA NA NA Negative Negative DNA B311 28.37 28.59 28.42 Candida albicans Candida albicans DNA B351 NA NA NA Negative Negative DNA B371 34.83 34.55 34.79 Aspergillus Aspergillus DNA C01 NA NA NA Negative Negative DNA C02 NA NA NA Negative Not tested DNA C04 NA NA NA Negative Negative DNA C05 NA NA NA Negative Not tested DNA C06 NA NA NA Negative Not tested DNA C07 NA NA NA Negative Not tested DNA C10 NA NA NA Negative Not tested DNA C12 NA NA NA Negative Not tested DNA C14 NA NA NA Negative Not tested DNA C16 34.01 34.07 34.18 Aspergillus fumigatus, Candida albicans Not tested DNA C17 32.49 32.22 32.54 Candida albicans Not tested DNA C18 30.53 30.92 30.73 Negative Pneumocystis jiroveci DNA C19 33.16 33.29 33.44 Candida glabrata Not tested DNA C21 NA NA NA Negative Negative DNA C22 NA NA NA Negative Negative DNA C23 32.93 32.52 32.67 Candida albicans Not tested DNA C24 NA NA NA Negative Not tested DNA C27 33.22 32.94 33.14 Negative Candida albicans DNA C28 29.91 30.07 30.04 Candida glabrata Candida glabrata, Aspergillus fumigatus DNA C33 NA NA NA Negative Not tested DNA C34 NA NA NA Negative Not tested DNA C38 33.07 32.91 32.82 Candida glabrata Not tested DNA C64 30.91 31.17 31.43 Candida albicans Candida albicans DNA C81 NA NA NA Negative Negative DNA C90 26.68 26.81 26.92 Candida albicans, Candida tropicalis Not tested .

[0100] result:

[0101] The present invention was used to test 39 clinical samples, including alveolar lavage fluid or sputum, as shown in Table 4. The results showed that all cases of positive pathogenic fungal culture could be detected as positive by the present invention; secondly, some samples were also detected as positive by the present invention, and the Ct value was relatively high, but the clinical culture results showed negative, and these samples were further verified by NGS results to support the test results of the present invention; finally, for Pneumocystis jiroveci, which cannot be cultured by clinical detection technology, two samples were found to be infected with Pneumocystis jiroveci (B131 and C18) by NGS, and the test of the present invention was also positive. In summary, the present invention is significantly superior to the clinical culture method in detecting pathogenic fungi, and can be used for the screening of pathogenic fungi in all patients who need antifungal preventive treatment, so as to avoid the abuse of antifungal drugs to prevent the development of drug resistance, and at the same time, it can save medical resources and reduce the economic burden on patients.

[0102] The above embodiments show and describe the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the above embodiments do not limit the present invention in any form, and any technical solution obtained by equivalent replacement or equivalent transformation falls within the protection scope of the present invention.

Claims

1. A method for detecting multiple pathogenic fungi using TaqMan probe method based on automatic fluorescence quantitative PCR algorithm, characterized in that: The following steps are involved: (1) Template DNA extraction: (11) Sample pretreatment: (12) Preparation of cracking system: (13) Automated nucleic acid extraction: (14) Collection of DNA: (2) TaqMan probe qPCR amplification reaction: (3) Result determination: The method is not intended for diagnosis or treatment of disease.

2. A primer and probe combination for simultaneously identifying multiple pathogenic fungi, characterized in that: The primers include: Forward primer F1: 5'-GCGCGYTACACTGACRGRGC-3' and Reverse primer R1: 5′-ACCTTGTTACGACTTTTASTTCCTCTAAATGACC-3′; The probe is Probe 1-MGB: 5'6-FAM-TCGTGCTGGGGATAGAGCAT-MGB 3'.

3. A detection reagent for simultaneously identifying multiple pathogenic fungi, characterized in that: The method comprises the primer and probe combination as claimed in claim 2.

4. A detection kit for simultaneously identifying multiple pathogenic fungi, characterized in that: The method comprises the primer and probe combination as claimed in claim 2.

5. The detection kit for simultaneously identifying multiple pathogenic fungi according to claim 4, characterized in that: The kit includes a TaqMan probe method qPCR amplification reaction system: (1) Reaction solution: AceQ reaction premix: AceQ U+Probe Master Mix; (2) Primer solution: including forward primer F1, reverse primer R1, and probe Probe 1-MGB. The primer and probe combinations are: Forward primer F1: 5′-GCGCGYTACACTGACRGRGC-3′; Reverse primer R1: 5′-ACCTTGTTACGACTTTTASTTCCTCTAAATGACC-3′; Probe 1Probe 1-MGB: 5'6-FAM-TCGTGCTGGGGATAGAGCAT-MGB 3'; (3) DEPC water: sterile water without nuclease.

6. The detection kit for simultaneously identifying multiple pathogenic fungi according to claim 5, characterized in that: The concentrations of the forward primer F1, the reverse primer R1 and the probe Probe 1-MGB were all 10 pmol / μl.

7. Use of the detection kit for simultaneously identifying multiple pathogenic fungi as claimed in claim 5, characterized in that: The following steps are involved: (1) Template DNA extraction: (11) Sample pretreatment: (12) Preparation of cracking system: (13) Automated nucleic acid extraction: (14) Collection of DNA: (2) TaqMan probe qPCR amplification reaction: (3) Result determination: The applications include scientific research or the development of related drugs, but do not include the diagnosis and treatment of diseases.

8. Use of the detection kit for simultaneously identifying multiple pathogenic fungi according to claim 7, characterized in that: The samples in (11) include one or more of sputum samples, alveolar lavage fluid samples and clinically isolated fungi.

9. Use of the detection kit for simultaneously identifying multiple pathogenic fungi according to claim 7, characterized in that: The (2) TaqMan probe method qPCR amplification reaction comprises the following steps: Use 200μl PCR tubes to prepare the reaction system, set up three replicates, forward primer F1 and reverse primer R1 are 0.4μl, probe Probe 1Probe 1-MGB 0.3μl, AceQ reaction premix 10μl, template DNA 2μl, make up to 20μl with DEPC-water, mix the reaction solution evenly and transfer it to a 96-well qPCR plate to avoid bubbles; use a sealing film to seal the tube mouth, place the above 96-well reaction tube on the qPCR instrument for amplification reaction; the reaction program is as follows: Stage 1 37℃, 3min; Stage 2 95℃, 5min; Stage 3 (95℃, 10s; 70℃, 20s), 40 cycles.

10. Use of the detection kit for simultaneously identifying multiple pathogenic fungi according to claim 7, characterized in that: The result determination of step (3) comprises the following steps: (31) When the positive control shows a Ct value and an "S"-shaped amplification curve, and the negative control has no Ct value and an "S"-shaped amplification curve, it indicates that there is no problem with the entire detection process and the test results of the sample to be tested are credible; (32) When the conditions in (1) are met, the detection well of the sample to be tested shows a Ct value and an "S"-shaped amplification curve, indicating that the pathogenic fungus in the sample to be tested is positive, or; the detection well of the sample to be tested does not show a Ct value and an "S"-shaped amplification curve, indicating that the pathogenic fungus in the sample to be tested is negative; (33) When the positive test conditions in (2) are met, combined with the standard curve, the content of pathogenic fungi decreases 10-fold for every increase of Ct by about 4; The Ct value of the test well of the sample to be tested meets the following conditions, that is, positive detection, and includes the intensity level classification of bacterial load: that is, 18≤Ct≤22, intensity level IV; 22≤Ct≤26, intensity level III; 26≤Ct≤30, intensity level II; 30≤Ct≤34, intensity level I; When the positive control lacks a Ct value or an "S"-shaped amplification curve, or the negative control has a Ct value and an "S"-shaped amplification curve, it indicates that there is a problem with the entire detection process, or there is contamination, and the test results of the sample to be tested are unreliable, and the test operation needs to be repeated to further determine the situation in the sample to be tested.

Citation Information

Patent Citations

  • Rapid Fungus detection kit and detection method using same

    CN101974640A

  • Primer probe combination and kit for efficiently detecting fungi in broad spectrum and application of primer probe combination and kit

    CN117467785A